Direct bone effects of calcimimetics in chronic kidney disease?
Level V
Where this comes from
- Record sourced from PubMed, PMID 31010472.
- Also identified by DOI 10.1016/j.kint.2019.01.045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Calcimimetics are widely used in patients on dialysis to treat secondary hyperparathyroidism. Our current view is that bone effects are only indirect through parathyroid hormone suppression. However, because bone cells express the calcium-sensing receptor, direct calcium-sensing receptor-mediated effects are also possible. New experimental data demonstrate direct anabolic bone actions of calcimimetics, independent of parathyroid hormone suppression. Because these effects could be clinically useful, further studies are necessary to confirm the validity of this observation.
Medical subject headings
- Hyperparathyroidism, Secondary
- Renal Insufficiency, Chronic